Annonce • May 23
Illumina, Inc. Announces Election of David P. King to Board of Directors, Effective May 21, 2026 Illumina, Inc. confirmed the election of David P. King to its Board of Directors, effective immediately following the company's annual meeting of shareholders on May 21, 2026. Mr. King's election marks an important addition to Illumina's Board as the company accelerates its clinical strategy to integrate genomics more broadly into the standard of care. Mr. King is the former Executive Chairman and Chief Executive Officer of Labcorp. Under his leadership, Labcorp entered the Fortune 500, and was recognized by Fortune as one of the World's Most Admired Companies. Mr. King joins the Board following the retirement of Frances Arnold, PhD, Robert S. Epstein, MD, and Gary S. Guthart, PhD, each of whom concluded distinguished tenures on the Board at the company's annual meeting. David P. King was elected to Illumina's Board of Directors in 2026. Mr. King has extensive experience in the healthcare and life sciences sectors in executive and non-executive roles, including leading complex businesses at scale, driving operational excellence and commercial initiatives, and executing transformational change through M&A and organic growth. Mr. King served as Chair and Chief Executive Officer as well as Executive Chairman of Laboratory Corporation of America Holdings (Labcorp) from 2007 to 2019. He provides strategic advisory services across the healthcare ecosystem through KingMan LLC. Mr. King also serves as Chair of Privia Health Group, Inc., as a director of Smith & Nephew, and has served in board leadership roles across a range of healthcare companies, including as Chair of ZimVie (2022–2025) and as Non-Executive Chair of PathGroup, LGC Limited, and AmSurg. Earlier in his career, Mr. King was a partner at Hogan & Hartson LLP (now Hogan Lovells) and served as an Assistant U.S. Attorney for the District of Maryland. Mr. King received a B.A. from Princeton University and a J.D. from the University of Pennsylvania Law School. New Risk • May 20
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €41m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Significant insider selling over the past 3 months (€41m sold). Annonce • May 03
Illumina, Inc. Revises Earnings Guidance for the Fiscal Year 2026 Illumina, Inc. revised earnings guidance for the fiscal year 2026. For the year, the company now expects total revenue of $4.52-$4.62 billion, a $20 million increase at the mid-point versus its prior guidance. Reported revenue growth of 4%-6%. Annonce • Apr 17
Illumina Inc. Launches Dragen Version 4.5 Software Illumina Inc. announced the launch of DRAGEN version 4.5 software (v4.5), one of the most substantial expansions of the software's capabilities to date. DRAGEN v4.5 delivers new ways to reduce noise, improve accuracy, and extract biological signals, giving researchers greater discovery power to fuel findings in rare disease and oncology. This release enhances DRAGEN's strong germline foundation with expanded pangenome representation and personalization, further improving variant calling accuracy and performance in challenging genomic regions. v4.5 provides analytical support for Illumina TruPath Genome, resolving challenging-to-map regions of the genome. DRAGEN v4.5 key updates: Significantly expands multiomic analysis, with structural variant calling and improved small variant accuracy for Illumina's 5-base solution, enabling more integrated genetic and epigenetic insight. Introduces machine-learning-driven somatic analysis and expands oncology insights with new capabilities like oncovirus detection. Strengthens the scalable multiomic pipelines that support ambitious projects, like the recently announced Billion Cell Atlas. Advances in v4.5 enhance secondary analysis in genomic and multiomic workflows. New algorithms support Illumina TruPath Genome: v4.5 introduces analytical support for TruPath, leveraging algorithmic advances to resolve 15 highly homologous, medically-relevant genes for rare disease research. Personalization improves germline variant calling: Personalization by default further reduces germline small variant errors, delivering approximately a 20% reduction in false positives and false negatives compared to v4.4. Pangenome better reflects global genomic diversity and reduces ancestry-related bias: The addition of Middle Eastern reference genomes expands the DRAGEN pangenome to better represent global population diversity, improving mapping and variant calling across underrepresented ancestries. In parallel, targeted improvements to the SMN1 variant caller enable detection of silent carriers, addressing a known source of underdiagnosis in certain populations. Machine learning expands Illumina's 5-base solution: The release introduces structural variant calling for both germline and somatic applications of 5-base, alongside improved germline small variant accuracy and personalization enabled by data specificity and machine learning. Illumina Connected Annotation further supports these analyses by highlighting genomic regions of interest informed by methylation data, simplifying interpretation of complex multiomic datasets. Formalin fixed paraffin embedded (FFPE) samples present substantial technical noise that can make it difficult to identify relevant variants. v4.5's machine-learning-driven somatic small variant calling reduces FFPE-associated false positives by over 90% for single nucleotide variants and over 87% for indels—improving sensitivity without increasing runtime or computational burden. Opt-in machine learning separates true variants and background artifacts, improving sensitivity at low tumor purity. This enables more reliable detection of biologically relevant variants in challenging samples. Additionally, v4.5 debuts robust oncovirus detection. Certain viruses, such as human papillomavirus (HPV), can drive cancer development by disrupting normal cellular control mechanisms, sometimes through integration of viral DNA into the host genome. In internal tests, v4.5 detected 100% of expected oncoviruses and identified 18 additional oncoviruses, showcasing the software's sensitivity for high-risk strains of HPV and Epstein-Barr Virus. The software is available via on-premises servers and in the cloud. Annonce • Apr 02
Illumina, Inc. Announces Board Retirements, Effective May 21, 2026 Illumina, Inc. announced that on April 2, 2026, each of Drs. Frances Arnold, Robert S. Epstein and Gary S. Guthart notified the Board of Directors of the Company of her or his intention to retire as a director of the Company, effective as of May 21, 2026 (the date of the Company’s 2026 annual meeting of stockholders). Buy Or Sell Opportunity • Mar 27
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to €103. The fair value is estimated to be €132, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.3% per annum. Earnings are also forecast to grow by 7.9% per annum over the same time period. Annonce • Feb 25
Illumina Launches TruPath Genome, Setting A New Standard in Genome in Genome Insights Illumina, Inc. announced the launch of TruPath Genome, setting a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and resolution—even across so-called "dark regions" of the genome—providing researchers with a more complete picture of genomic alterations implicated in genetic disease. With an incredibly simple workflow, TruPath Genome eliminates traditional library prep. In about 10 minutes of hands-on time, TruPath Genome generates 16 whole genomes per day, nearly double the throughput of competing long-read methods, and with fewer errors. TruPath Genome leverages novel on-flow cell library preparation with patterned flow cell technology and advanced informatics to seamlessly add long-distance insights for comprehensive variant detection. DRAGEN algorithms tuned to incorporate proximity information from TruPath flow cells improve read alignment and variant calling, extending Illumina high-quality reads to difficult-to-map regions, variant phasing, structural variants, short tandem repeats (STR), and clinically relevant paralogous genes. TruPath Genome fully phases up to 98% of genes. TruPath Genome delivers a highly cost-effective whole genome workflow solution at a USD 395 list price. This includes all consumables and analysis, at an industry standard depth of at least 30x coverage with single-use flow cell, which is critical in clinical research. Data presented at AGBT and in previous publications illustrates how TruPath Genome is already shedding light on some of the most challenging genetic diseases, including spinal muscular atrophy, kidney disease, and complex adrenal disorders. Researchers at University Medical Center Utrecht presented data evaluating TruPath Genome in challenging rare disease samples, with a particular focus on long-range phasing performance required to support non-invasive prenatal diagnostic (NIPD) assays, as well as resolution of difficult genomic regions and complex structural variants. At the recent Festival of Genomics & Biodata in London, researchers from the University of Exeter shared data on their pilot of TruPath Genome, which found that the technology resolved highly complex genomic regions, including a gene known to be associated with inherited adrenal disorders. While current short-read WGS requires parental samples to identify compound heterozygotes, TruPath Genome offers a single-sample path to these insights, improving coverage for samples processed without parental data. Broad Clinical Labs is among the first to adopt TruPath Genome, which will make this important technology available to their collaborators in rare disease research. More than 30 early access customers have been piloting the technology over the past 16 months, including GeneDx, Rady Children's Hospital, and Baylor College of Medicine. Baylor College of Medicine recently published a pre-print on the technology in medRxiv. The TruPath Genome launch was unveiled during the Gold Sponsor Workshop at the Advances in Genome Biology and Technology (AGBT) annual meeting in Orlando. Annonce • Feb 24
Illumina, Inc. Unveils Roadmap of Groundbreaking NovaSeq X Advancements in Data Quality, Output, Speed, and Flexibility Illumina, Inc. unveiled an 18-month roadmap of innovations that enhance the power and value of the NovaSeq X system. Updates include technology that will deliver up to a Q70 quality score for the first time, along with 30% increased speed and output up to 35 billion reads (35B). staggered starts and new flow cells go live across the customer base in the coming weeks. Together, these advances increase daily sequencing productivity and expand the range of applications that can be run at scale on a single instrument. With higher output, increased accuracy, faster run times, and new flexible workflow modes, the roadmap delivers compounded value for customers seeking better, faster, and more cost-effective sequencing for their most demanding applications. Improved accuracy ushers in a new era for applications that require ultrasensitivity. Upon rollout, these updates will enhance the performance and value of the 8901 NovaSeq X systems installed globally--the world's largest high-throughput sequencing fleet. These advances--together with a growing portfolio of multiomic and oncology-focused assays--accelerate Illumina's ability to deliver higher-quality data at a lower total cost. The updates also set the company on track to scale access to whole-genome sequencing research in oncology, including highly sensitive molecular residual disease (MRD) testing, and genetic disease. Key product enhancements expected to be rolled out over the next 18 months include: Data quality: Illumina will introduce Q70 quality score technology, enabling cutting-edge oncology applications with unmatched accuracy. Output: NovaSeq X output will increase from 25B to 35B (a 40% uptick) and 10B will increase to 14B, enabling larger and more complex studies on the same instrument. Flexibility: Illumina will provide enhanced batching flexibility and new high-throughput modes, optimizing flow cell usage to improve read volume for single-cell, proteomics, and Perturb-seq applications. In the coming weeks, Illumina will introduce new flow cells, staggered starts, and software enhancements that expand the sequencer's applications. Flow cells: 5B kits present a mid-size batching option ideally suited for proteomic studies. Among the important factors to which company business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) ability to successfully implement NovaSeq X updates on a cost-effective and timely basis, (ii) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (iii) ability to manufacture robust instrumentation and consumables and develop reliable software solutions; and (iv) the acceptance and adoption by customers. Buy Or Sell Opportunity • Feb 20
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 6.6% to €100. The fair value is estimated to be €127, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings are also forecast to grow by 8.1% per annum over the same time period. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €95.40, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 16x in the Life Sciences industry in Europe. Total loss to shareholders of 51% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €125 per share. Reported Earnings • Feb 07
Full year 2025 earnings released: EPS: US$5.48 (vs US$7.69 loss in FY 2024) Full year 2025 results: EPS: US$5.48 (up from US$7.69 loss in FY 2024). Revenue: US$4.34b (flat on FY 2024). Net income: US$850.0m (up US$2.07b from FY 2024). Profit margin: 20% (up from net loss in FY 2024). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Annonce • Feb 06
Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2026 Illumina, Inc. provided earnings guidance for the fiscal year 2026. For the year, the company expects total revenue to be between $4.5 billion to $4.6 billion, representing growth of 4% to 6% on a reported basis, including a 1.5% to 2.0% benefit from the recently closed SomaLogic acquisition. Buy Or Sell Opportunity • Feb 02
Now 21% undervalued Over the last 90 days, the stock has risen 14% to €119. The fair value is estimated to be €151, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 11% per annum over the same time period. Annonce • Jan 31
Illumina, Inc. (NasdaqGS:ILMN) completed the acquisition of SomaLogic, Inc., Sengenics Corporation LLC and Sengenics Corporation Pte Ltd from Standard BioTools Inc. (NasdaqGS:LAB). Illumina, Inc. (NasdaqGS:ILMN) entered into an agreement to acquire SomaLogic, Inc., Sengenics Corporation LLC and Sengenics Corporation Pte Ltd from Standard BioTools Inc. (NasdaqGS:LAB) for approximately $430 million on June 22, 2025. Under the terms of the transaction, Standard BioTools will receive an upfront payment of $350 million in cash, payable at the closing of the transaction, subject to customary adjustments, and up to $75 million in earnout payments, payable upon the achievement of specified targets for net revenue generated from SOMAmer-based assay services and sales of certain SOMAmer-based NGS library preparation kits and array kits in fiscal years 2025 and 2026. Standard BioTools will also receive a 2% royalty on net revenues generated from sales of SOMAmer-based NGS library preparation kits for 10 years following the closing of the transaction and a co-exclusive license for the intellectual property relating to Single SOMAmer commercialization in singleplex affinity assays. If the agreement is terminated under specified circumstances, Illumina will be required to pay Standard BioTools a reverse termination fee in cash equal to $14.5 million.
The consummation of the Transaction is subject to customary closing conditions, including, among others, the expiration or termination of the applicable waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other regulatory approvals. The transaction has been unanimously approved by both the Standard BioTools Board of Directors and a Special Committee of the Standard BioTools Board of Directors. The transaction is expected to close in the first half of 2026.
Centerview Partners LLC is serving as financial advisor and fairness opinion provider to Standard BioTools, and Damien Zoubek and Jenny Hochenberg of Freshfields US LLP and Richards, Layton & Finger, P.A. are serving as its legal counsel. UBS Securities LLC is serving as financial advisor and fairness opinion provider to the Special Committee of the Standard BioTools Board of Directors. Goldman Sachs and Co. LLC is serving as financial advisor and Ting Chen and Daniel Cerqueira of Cravath, Swaine & Moore LLP are serving as legal advisor to Illumina. Allison Schneirov, Christopher Barlow of Skadden, Arps, Slate, Meagher & Flom LLP represented Centerview Partners LLC as financial advisor to Standard BioTools Inc.
Illumina, Inc. (NasdaqGS:ILMN) completed the acquisition of SomaLogic, Inc., Sengenics Corporation LLC and Sengenics Corporation Pte Ltd from Standard BioTools Inc. (NasdaqGS:LAB) on January 30, 2026. The deal was funded with cash on hand Annonce • Jan 20
Illumina, Inc. Secures CMS Reimbursement for TruSight Oncology Comprehensive, Expanding Access to Precision Oncology Illumina, Inc. announced that reimbursement has been granted for its FDA-approved in vitro diagnostic (IVD) TruSight Oncology (TSO) Comprehensive test. The reimbursement decision from the Centers for Medicare and Medicaid Services (CMS) will expand access to comprehensive genomic profiling (CGP) and the growing role of personalized genomics in oncology care. TSO Comprehensive gives clinicians the ability to simultaneously assess hundreds of genes--including relevant cancer biomarkers--to inform treatment decisions. With reimbursement now in place, more laboratories will be able to bring CGP in-house and deliver clinically actionable results to their patients, closer to the point of care. TSO Comprehensive enables laboratories of all sizes to deliver FDA-approved, clinically valuable genomic insights that are easy to access and implement. This promotes broader access to precision oncology diagnostics across academic medical centers, healthcare networks, hospitals, and regional reference laboratories. Effective January 1, 2026, TSO Comprehensive is reimbursed under the Clinical Laboratory Fee Schedule at a rate of $2,989.55 using Proprietary Laboratory Analysis (PLA) code 0543U, which establishes a clear and predictable reimbursement pathway for all Medicare beneficiaries. Clinical demand for genomic testing is growing at every level of the health care ecosystem. With that demand comes opportunity for better health care and improved quality of life by advancing access to and adoption of tests like TSO Comprehensive. Earlier this month, Illumina reported preliminary unaudited financials for the fourth quarter and fiscal year 2025, which highlighted clinical markets as a key driver of growth. Roughly 60% of the company's sequencing consumables revenue was driven by clinical customers last year. Annonce • Jan 13
Illumina, Inc. to Report Q4, 2025 Results on Feb 05, 2026 Illumina, Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Feb 05, 2026 Buy Or Sell Opportunity • Jan 10
Now 23% undervalued Over the last 90 days, the stock has risen 52% to €121. The fair value is estimated to be €157, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 4.8% per annum. Earnings are also forecast to grow by 9.5% per annum over the same time period. Annonce • Jan 09
Illumina, Inc. Appoints Eric D. Green as Chief Medical Officer, Effective February 2, 2026 Illumina, Inc. announced the appointment of Eric D. Green, M.D., Ph.D., as Chief Medical Officer, effective February 2, 2026. In this role reporting to the CEO, Dr. Green will accelerate the company's mission to drive a revolution in medicine by unlocking the power of the genome. Dr. Green will serve as a key scientific and medical leader representing Illumina, helping advance the clinical use of genomics, expand access to precision medicine solutions, and increase the diversity of genomics data. Dr. Green's unique expertise, knowledge, and influence with partners, KOLs, and medical professionals will serve as a critical component in Illumina's strategic efforts to improve human health through genomics on a global level. As Chief Medical Officer, Dr. Green will be part of Illumina's Executive Leadership Team and will be a champion for the company's mission, technology roadmap, and growing clinical impact. Dr. Green is widely regarded as one of the most influential leaders in genomics since the field's inception. He joins Illumina after more than three decades at the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health. As the NHGRI Director from 2009 to 2025, he helped guide the transformation of genomics from a primarily research-driven field into a foundational element of modern medicine and public health. Dr. Green trained as a physician scientist, earning an M.D. and Ph.D. from Washington University School of Medicine. During his residency training in clinical pathology (laboratory medicine), he launched his career in genomics. Several years later, he became a beginning-to-end participant in the Human Genome Project and emerged as an international genomics leader. Annonce • Jan 07
Illumina Launches Powerful Software for Connected, Intuitive, and Scalable Multiomic Analysis Illumina, Inc. announced the release of Illumina Connected Multiomics, a powerful cloud-based research software platform to analyze and visualize multiomic and multimodal biological data at scale. As multiomic datasets grow rapidly in size and complexity, researchers need easy-to-use tools to integrate information across transcriptomics, genomics, proteomics, epigenetics, and more. Connected Multiomics addresses this challenge by bringing multiomic data together in a single platform, reducing time, cost, and complexity, enabling scientists to accelerate discovery and advance precision medicine. Connected Multiomics officially launched last month following a year of valuable input from 40 early access users. At the University of Colorado Anschutz Medical School, oncology researchers used the technology to uncover new insights on melanoma through analysis of proteomic data. Simplifying the multiomic analysis experience: Connected Multiomics can aggregate thousands of multiomic samples from Illumina and third-party assays in a single analysis. It provides reproducible results and interactive multiomic visualizations in one integrated, cloud-based analysis environment using industry standard statistical methods and integrated DRAGEN secondary analysis. Additionally, AI-enabled variant interpretation, using PrimateAI and PromoterAI, removes background mutations and points to the most biologically meaningful multiomic signals earlier in the analysis process. For spatial transcriptomics, Connected Multiomics overlays gene expression data on tissue imagery to provide rich spatial context for biological insights. Illumina is building the most comprehensive multiomic solutions in the industry, anchored on its world-class sequencing platforms for unmatched quality and scale. For research and pharma innovators, these solutions unlock the next wave of precision health discovery, accelerating breakthroughs in biology and drug development. Annonce • Nov 11
Illumina Protein Prep Delivers Groundbreaking Precision in NGS Proteomics for More Than 40 Customers, Ranging from Academic Institutions to Large National Biobanks Illumina, Inc. announced that Illumina Protein Prep is delivering the broadest coverage of the blood proteome on the market at the lowest cost per protein target for more than 40 customers across 16 sites globally. Labs of all sizes are creating powerful layers of genome data for a range of diseases that enrich datasets generated by biobank programs around the world. Illumina Protein Prep empowers researchers to seamlessly integrate comprehensive proteomics into large-scalegenomics studies, dramatically accelerating breakthroughs across cancer and cardiometabolic and immunologic diseases. Illumina is providing the AI-driven infrastructure to fully realize this vision with DRAGEN and Illumina Connected Multiomics, delivering both secondary and tertiary analysis in one workflow. Depending on the use case, the Illumina Protein Prep solution offers an accessible alternative or complement to mass spectrometry, allowing researchers to derive transformative insights, increasing their discovery power. Sydney Mass Spectrometry adopts Illumina Protein Prep to expand proteomic offerings. As the first facility in the wider Asia Pacific region to offer Illumina Protein Prep, Sydney Mass Spectrometry recently completed their first real-world experiment using blood plasma samples from a clinical trial to study dietary interventions in subjects with metabolic disease. Illumina Protein Prep identified significant differences between cohorts on a grouped basis, leading researchers on a path to further validate several novel candidates. Now, proteomics is creating the vital bridge between population-specific genetic variants and their affected proteins. Singapore's PRECISE-SG100K study is using Illumina Protein Prep to run 10,000 plasma samples to expand upon its previous proteomic profiling project, with a goal to develop a standardized dataset that can be used to interactate potential therapeutic targets. Recent Insider Transactions • Nov 09
Independent Chairman recently bought €53k worth of stock On the 3rd of November, Scott Gottlieb bought around 500 shares on-market at roughly €106 per share. This transaction amounted to 6.1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Scott's only on-market trade for the last 12 months. Buy Or Sell Opportunity • Nov 06
Now 22% undervalued Over the last 90 days, the stock has risen 28% to €103. The fair value is estimated to be €132, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 4.4% per annum. Earnings are also forecast to grow by 8.7% per annum over the same time period. Annonce • Nov 06
Illumina, Inc. Responds to Positive Updates from Chinese Ministry of Commerce The Chinese Ministry of Commerce (MOFCOM) announced it will lift the export ban on Illumina, Inc., which had been in place since March 4, 2025. While the ban will be lifted on November 10, Illumina remains on the Unreliable Entities List (UEL), requiring government approval for instrument purchases. Illumina remains focused on achieving a positive resolution regarding its inclusion on the UEL and is committed to serving customers in this important market. For two decades, Illumina has been proud to partner with customers in China to advance genomics and improve human health. Reported Earnings • Oct 31
Third quarter 2025 earnings released: EPS: US$0.98 (vs US$4.43 in 3Q 2024) Third quarter 2025 results: EPS: US$0.98 (down from US$4.43 in 3Q 2024). Revenue: US$1.08b (flat on 3Q 2024). Net income: US$150.0m (down 79% from 3Q 2024). Profit margin: 14% (down from 65% in 3Q 2024). Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Annonce • Oct 31
Illumina, Inc. Revises Earnings Guidance for the Year 2025 Illumina, Inc. revised earnings guidance for the year 2025. On a reported basis, that equates to Illumina revenue in the range of $4.27 billion to $4.31 billion, up $20 million at the midpoint relative to last guidance. Annonce • Oct 01
Illumina, Inc. Appoints Rami Mehio as Senior Vice President and General Manager of BioInsight Illumina, Inc. announced the launch of BioInsight, a new business within Illumina. BioInsight will be led by Rami Mehio as senior vice president and general manager. Mehio has led Illumina's Global Software & Informatics team for four years and now joins the company's executive leadership team. BioInsight, under Rami's guidance, will strengthen Illumina's leadership at the intersection of sequencing, software, and AI, with a focus on supporting pharma in drug target discovery and development. Annonce • Sep 23
Illumina Inc. Advances Personalized Cancer Care with New Pharma Development Partners Illumina Inc. will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight™? Oncology (TSO) Comprehensive genomic profiling test. The continued expansion of tumor-agnostic CDx claims underscores Illumina's commitment to advance access for patients to precision oncology care by generating standardized, globally distributable tests. The new companion diagnostic partnerships will focus on KRAS alterations, which are known to cause uncontrolled cell growth, leading to cancer. TSO Comprehensive help clinicians match patients with approved targeted therapies based on the genetic mutations underlying their cancer. TSO Comprehensive does this by generating a molecular tumor profile that can identify the genetic mutations driving cancer growth. To target those underlying mutations, clinicians use the CDx to confirm whether a patient is a candidate for a targeted therapy or clinical trial. KRAS is one of the most commonly mutated oncogenes in cancer, driving tumor proliferation, survival, and progression. Given its prominence in cellular transformation, previous research has demonstrated that identifying KRAS variants is critical for proper therapy selection and improving patient outcomes. Genomics paves the way in precision oncology: Recent advances using genomics to detect KRAS variants have been successfully demonstrated across cancer types despite historical challenges in targeting KRAS. This includes traditionally difficult-to-treat diseases like pancreatic ductal adenocarcinoma, leading to opportunities for improved prognostication and treatment decisions. Genomics insights into KRAS both enhance understanding of KRAS-driven tumor biology and pave the way for more personalized therapeutic strategies. Annonce • Sep 04
Illumina®? Protein Prep Launches to Drive Greater Proteomic Insights for Improved Drug Discovery and Development Illumina Inc. announced the launch of Illumina Protein Prep, an assay introducing superior performance for next-generation sequencing (NGS) based proteomics discovery at scale. Illumina Protein Prep has been available through an early-access program, and is now broadly available to customers worldwide, enabling researchers to add proteomics to large-scale genomics studies and fuel new insights across cancer and cardio metabolic and immunologic diseases, with a streamlined sample-to-insights solution for discovery and clinical research.roteomics offers a view into proteins and their functions in biologic processes. Understanding their roles in gene expression and how proteins change throughout disease states is critical to biomarker discovery and precision therapy development. Early access customers commend scale, high consistency, and easy workflow. Since 2024, Illumina has worked with nearly 40 early collaborators to pilot Illumina Protein Prep, informing development and leading to an optimized customer experience. Since the inception of early access, about 30,000 samples have been processed with the Illumina Protein Prep 6K assay and over 6000 samples with the Illumina Protein Prep 9.5K assay, which was made available through early access this March. Illumina Protein Prep accelerates global discovery initiative in rare disease Proteomic studies bridge the gap between genotype and phenotype, providing a real-time snapshot of cellular activity between healthy and disease states. In January, Illumina announced a pilot proteomics program with UK Biobank and a consortium of biopharma collaborators to analyze 50,000 samples with Illumina Protein Prep, the NovaSeq X Plus System, and the DRAGEN Protein Prep Quantification pipeline. The study will generate a new collection of high-quality, NGS-based proteomics data for the research community and pharma partners to advance biological insights. In June, Illumina announced a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology. The move enhances Illumina's presence in the expanding proteomics market, advances the company's multiomics strategy, and reinforces the value of the NovaSeq X Series as an enabler of the next generation of multiomic applications. Once the transaction closes, Illumina platforms will continue to support all NGS-based proteomics solutions. Annonce • Aug 01
Illumina, Inc. Revises Earnings Guidance for the Fiscal Year 2025 Illumina, Inc. revised earnings guidance for the fiscal year 2025. For the year, the company expected total company constant currency revenue decline in the range of 2.5% to 0.5%, up from previous guidance of decline of 3% to 1%. Annonce • Jul 30
Illumina Enhances Assay to Accelerate Access to Comprehensive Tumumarker Testing Illumina Inc. announced the launch of the next generation of TruSight Oncology 500, its cancer research assay that enables comprehensive genomic profiling. Comprehensive genomic profiling (CGP) is a critical tool to accelerate access to precision medicine by providing a molecular tumor profile to labs advancing research in therapy selection and clinical trial eligibility. TruSight Oncology500 version 2 (TSO 500 v2) offers a streamlined sample-to-analysis workflow and reflects Illumina's commitment to serving customers with the highest quality and most rigorously tested solutions. From a small tissue sample, TSO 500 v2 assesses hundreds of genes across all variant classes and immuno-oncology biomarkers to facilitate therapy selection research. "The new workflow is fast and streamlined with HRD included. Turnaround time is very important to lab so we can quickly access results. The solution will also allow us to minimize service costs by consolidating our tests on Illumina sequencers." Key advantages included in TSO 500 v2: Streamlined workflow reduces turnaround time and hands-on time; Sensitive variant calling and improved coverage of difficult genomic regions; Leverages gold-standard Myriad Genomic Instability Score (GIS) algorithm to determine HRD status, included for all samples; Improved sustainability: New kit configurations with 50% less packaging, 70% fewer tubes, and improved usability with a color-coded tubing system; Integrated and automated data analysis, from sequencer to insights, supported with DRAGEN™? secondary analysis and Illumina Connected Insights for variant interpretation, or with third-party solutions like Velsera Clinical Genomics Workspace (CGW); Broad platform compatibility across high- and mid-throughput sequencers; User-friendly automation kits and methods (coming soon) that furtherred reduce turnaround time andhands-on time compared to the manual workflow. Another early access customer, Conxi Lazaro, PhD, lab director at the Barcelona Institute of Oncology, noted the impact of the updated packaging and kit configuration on the user experience: "There are far fewer boxes and tubes to manage, which means we spend less time unboxing and can work faster and more efficiently. Use of forward-looking statements: This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which company business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, manufacturing, and launching new products and services; (ii) customer uptake of, and satisfaction with, new products and services; (iii) ability to manufacture robust instrumentation and consumables; (iv) the future conduct and growth of the business and the markets in which company operate; and (v) legislative, regulatory and economic developments, together with other factors detailed in its filings with the Securities and Exchange Commission, including its most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released before. Annonce • Jul 11
Illumina, Inc. to Report Q2, 2025 Results on Jul 31, 2025 Illumina, Inc. announced that they will report Q2, 2025 results After-Market on Jul 31, 2025 Annonce • Jun 24
Illumina, Inc. (NasdaqGS:ILMN) entered into an agreement to acquire SomaLogic, Inc. from Standard BioTools Inc. (NasdaqGS:LAB) for approximately $430 million. Illumina, Inc. (NasdaqGS:ILMN) entered into an agreement to acquire SomaLogic, Inc. from Standard BioTools Inc. (NasdaqGS:LAB) for approximately $430 million on June 22, 2025. Under the terms of the transaction, Standard BioTools will receive an upfront payment of $350 million in cash, payable at the closing of the transaction, subject to customary adjustments, and up to $75 million in earnout payments, payable upon the achievement of specified targets for net revenue generated from SOMAmer-based assay services and sales of certain SOMAmer-based NGS library preparation kits and array kits in fiscal years 2025 and 2026. Standard BioTools will also receive a 2% royalty on net revenues generated from sales of SOMAmer-based NGS library preparation kits for 10 years following the closing of the transaction and a co-exclusive license for the intellectual property relating to Single SOMAmer commercialization in singleplex affinity assays. If the agreement is terminated under specified circumstances, Illumina will be required to pay Standard BioTools a reverse termination fee in cash equal to $14.5 million.
The consummation of the Transaction is subject to customary closing conditions, including, among others, the expiration or termination of the applicable waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other regulatory approvals. The transaction has been unanimously approved by both the Standard BioTools Board of Directors and a Special Committee of the Standard BioTools Board of Directors. The transaction is expected to close in the first half of 2026.
Centerview Partners LLC is serving as financial advisor and fairness opinion provider to Standard BioTools, and Damien Zoubek and Jenny Hochenberg of Freshfields US LLP and Richards, Layton & Finger, P.A. are serving as its legal counsel. UBS Securities LLC is serving as financial advisor and fairness opinion provider to the Special Committee of the Standard BioTools Board of Directors. Goldman Sachs and Co. LLC is serving as financial advisor and Ting Chen and Daniel Cerqueira of Cravath, Swaine & Moore LLP are serving as legal advisor to Illumina. Allison Schneirov, Christopher Barlow of Skadden, Arps, Slate, Meagher & Flom LLP represented Centerview Partners LLC as financial advisor to Standard BioTools Inc. Annonce • May 30
Illumina Inc. Unveils PromoterAI, Groundbreaking Algorithm to Accelerate Insights for Rare Disease Diagnosis Illumina Inc. unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published in Science illustrates how this deep learning technology discovered regulatory variants in noncoding "promoter" segments that contribute up to 6% of the genetic causes of rare diseases. By turning data into insights, this technology is expected to help researchers accelerate new breakthroughs in diagnosis for rare diseases. When promoters are disrupted by genetic mutations, it can have profound consequences for downstream gene expression. The PromoterAI algorithm interprets the genetic sequence of promoters, thus opening the door to precise diagnoses for more patients with rare diseases. With PromoterAI applied to whole-genome sequencing (WGS) data analysis, clinical researchers are empowered to better understand the etiology and drug target potential for rare genetic diseases, common diseases, and oncology. PromoterAI is the latest genomic AI algorithmic innovation from Illumina. In 2019, the Illumina Artificial Intelligence Lab released SpliceAI, a deep learning tool for interpreting noncoding cryptic splice mutations. In 2023, Illumina released PrimateAI-3D, which predicts the pathogenicity of protein-coding variants based on evolutionary conservation and protein structure. The study demonstrates that when used together, Illumina's AI classification prediction tools--PromoterAI, PrimateAI-3 D, and SpliceAI--effectively double the diagnostic yield compared to using protein-truncating variants alone. PromoterAI will be accessible through Illumina Connected Software and it is available as part of DRAGEN™? secondary analysis. Precomputed PromoterAI scores for all human promoter single-nucleotide variants are freely available for academic and noncommercial research use. Illumina Connected Software supports seamless integration with next-generation sequencing and array workflows for genomics and multiomics. Researchers, bioinformaticians, and clinical geneticists can use Illumina Connected Software to prioritize variants that are important to a case, gain critical insights, and accelerate their precision medicine dry lab operations. Annonce • May 28
Illumina Expands Clinical Oncology Portfolio Unlocking New Standard of Care and Access to Precision Therapies Illumina Inc. announced an expanded clinical oncology portfolio, unlocking the next new solutions to advance precision oncology and improve the standard of care. The company's broad range of clinical offerings will accelerate access to precision oncology for more patients with cancer. Illumina tumor profiling and in vitro diagnostic (IVD) solutions will be on display at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Illumina TruSight (TSO) Comprehensive is the first and only FDA-approved test offering a distributable comprehensive genomic profiling IVD kit with pan-cancer CDx claims, evaluating both DNA and RNA. This enables clinicians to rapidly match cancer patients with targeted therapies using comprehensive tumor profiling. Illumina customers across the US -- in community oncology care practices, regional hospitals and health systems, and academic medical centers -- are integrating TSO Comprehensive into their clinical practice. This month, UofL Health - UofL Hospital became the first Illumina customer to begin offering the test to patients. Annonce • May 14
Illumina Inc. Announces the Launch of DRAGEN Version 4.4 Software (v4.4) Illumina Inc. announced the launch of DRAGEN™? version 4.4 software (v4.4), the industry's most comprehensive secondary analysis solution. The latest version of DRAGEN includes out-of-the-box oncology applications for clinical research and support for newly announced Illumina multiomics assays. Additionally, DRAGEN v4.4 continues DRAGEN's best-in-class accuracy with a 30% improvement in germline structural variant calling accuracy. DRAGEN v4.4 enhancements will simplify NGS analysis for customers while expanding their capabilities. Providing labs with ready-to-use analysis applications simplifies oncology biomarker detection and reduces complexities for customers. The applications integrate with the Illumina Connected Insights platform, allowing for a fully streamlined analysis and interpretation workflow, and enabling efficient and complete discovery and clinical research solutions across a wide range of customer segments, including genetic disease, oncology, multiomics, infectious disease, and population genomics. University hospital selects DRAGEN for pioneering clinical impact study. The University Hospital of Tubingen (UHT) in Germany is among the first adopters of the latest version of DRAGEN. Researchers will compare the diagnostic yield of WGS processed with DRAGEN v4.4 and WGS processed initially using their existing, in-house analysis software pipeline. DRAGEN germline analysis is regarded as the most accurate variant calling tool available for germline WGS testing. This was demonstrated in a peer-reviewed study published in Nature Biotechnology in October 2024, "Comprehensive genome analysis and variant detection at scale using DRAGEN," which validated DRAGEN software's germline algorithms and proved their superior performance in providing a more comprehensive genome with higher accuracy and faster reads compared to eight other variant calling programs in the study. Key features of DRAGEN v4.4: Preconfigured applications: DRAGEN v4.4 will offer " push-button" analysis for oncology workflows, including the first and only commercially available heme WGS application, Solid WGS DNA Tumor- Normal, and pipelines for molecular residual disease (MRD), WGS analysis, with more coming soon. New multiomics pipelines: Support for new and emerging multiomics assays includes Illumina Single Cell 3'RNA Prep, Illumina Protein Prep, and in the future will support the anticipated 5-base solution for methylation analysis, and Illumina's spatial technology solution. Annonce • May 09
Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2025 llumina, Inc. provided earnings guidance for the fiscal year 2025. For fiscal year 2025, the company continues to expect Core Illumina revenue to decline between 1% and 3% on a constant currency basis year over year, down from low single digit growth previously. Annonce • May 01
Illumina, Inc. and Ovation.io Launches First-Of-Kind GLP-1 Dataset to Accelerate New Therapy Development Illumina, Inc. and Ovation.io, Inc. announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies. The dataset will be made available to the pharma community to advance drug discovery and development. This collaboration is the latest in a series of efforts to partner across the ecosystem, and deploy multimodal data to advance a deeper understanding of biology. One in eight adults in the United States have used a GLP-1 receptor agonist, according to a 2024 health tracking poll conducted by the Kaiser Family Foundation. The initiative leverages end-to-end Illumina NGS technologies to sequence 25,000 whole genomes and to profile the protein expression of 5,000 samples, using the Illumina Protein Prep (IPP) assay, which detects 9,500 human proteins per sample. The initiative aims to include a longitudinal subset of proteomes from paired samples collected before and after patient exposure to GLP-1 therapy. IP enables the discovery of new protein quantitative trait loci (pQTL), which are emerging as a vital tool for drug discovery, linking genetic variation with protein expression data and disease or other phenotypes. The pQTL dataset is processed using Illumina's DRAGEN secondary analysis and the newly released Illumina Connected Multiomics for tertiary analysis and visualizations. The data is stored for future large-scale studies in Illumina Connected Analytics. Ovation is providing samples from its biobank of over 1.7 million de-identified, consented, and tokenized samples, linked to rich, longitudinal phenotypic data. The companies plan to explore opportunities to scale the GLP-1 dataset and generate others in the future. Annonce • Apr 12
Illumina, Inc., Annual General Meeting, May 21, 2025 Illumina, Inc., Annual General Meeting, May 21, 2025. Annonce • Apr 11
Illumina, Inc. to Report Q1, 2025 Results on May 08, 2025 Illumina, Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025 Annonce • Mar 25
Illumina, Inc. Announces Board Changes Illumina, Inc. announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief Investment Officer of Corvex Management, will join the Board of Directors on March 28, 2025. Stephen MacMillan, Chairman, President, and CEO of Hologic, who joined the Illumina Board in June 2023, has decided to retire from the board in preparation for the company's upcoming annual meeting of shareholders. Scott Gottlieb was appointed to Illumina's Board in February 2020. Dr. Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration from 2017 to 2019. He is currently a Partner at the venture capital firm New Enterprise Associates and a Senior Fellow at the American Enterprise Institute for Public Policy Research. He serves as a director of the publicly traded companies Pfizer, Inc. and TempusAI, and is a member of the executive committee of the board of the Mount Sinai Medical System. Dr. Gottlieb is an elected member of the National Academy of Medicine. Keith Meister is Managing Partner and Chief Investment Officer of Corvex Management LP, which he founded in December 2010. Mr. Meister currently serves on the boards of directors for MGM Resorts, GeneDx and Vestis. He is Chairman of the board of directors of the Harlem Children's Zone and a member of the board of trustees for the American Museum of Natural History. 
